{"id":417647,"date":"2021-01-20T07:48:16","date_gmt":"2021-01-20T12:48:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=417647"},"modified":"2021-01-20T07:48:16","modified_gmt":"2021-01-20T12:48:16","slug":"tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/","title":{"rendered":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med<\/b><\/p>\n<p class=\"bwalignc\">\n-Conference to be held at 4:30 pm EST on January 21, 2021-\n<\/p>\n<p>MORRISVILLE, N.C.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host an investor conference call for analysts and investors on Thursday, January 21, 2021 at 4:30 p.m. EST. On the call, management will review the previously announced acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH), and the clinical development plan to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.\n<\/p>\n<p>\nA live webcast of the conference call and accompanying slides will be available under \u201cEvents and Presentations\u201d in the Investors section of the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.tenaxthera.com%2FTENX%2Fcorporate_document%2F1327&amp;esheet=52364194&amp;newsitemid=20210120005056&amp;lan=en-US&amp;anchor=investors.tenaxthera.com&amp;index=1&amp;md5=eee58d7327b40ea17dfeae643ee86fe9\">investors.tenaxthera.com<\/a>. The conference call can be accessed by dialing (877) 405-1242 from the U.S. and (201) 389-0852 internationally, followed by the conference ID: 13715313. An archived webinar recording of the event will be available on the website for approximately 30 days.\n<\/p>\n<p><strong>About Tenax Therapeutics<\/strong><\/p>\n<p>\nTenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tenaxthera.com&amp;esheet=52364194&amp;newsitemid=20210120005056&amp;lan=en-US&amp;anchor=www.tenaxthera.com&amp;index=2&amp;md5=f356c363d0f026d5bb9968829e204b1e\">www.tenaxthera.com<\/a>.\n<\/p>\n<p><b>About Levosimendan<\/b><\/p>\n<p>\nLevosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.\n<\/p>\n<p><b>About Imatinib<\/b><\/p>\n<p>\nImatinib is an antiproliferative agent developed to target the BCR-ABL tyrosine kinase in patients with chronic myeloid leukemia. The inhibitory effects of imatinib on PDGF receptors and c-KIT suggested that it may be efficacious in PAH. Imatinib reversed experimentally induced pulmonary hypertension and has pulmonary vasodilatory effects in animal models and proapoptotic effects on pulmonary artery smooth muscle cells from patients with idiopathic PAH. In a phase 3 clinical trial imatinib produced significant improvements in exercise capacity, but a high rate of dropouts attributed largely to gastric intolerance prevented regulatory approval.\n<\/p>\n<p><b>Caution Regarding Forward-Looking Statements <\/b><\/p>\n<p>\nThis news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the Company\u2019s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the Company\u2019s control that could lead to delays in the clinical study, new product introductions and customer acceptance of these new products; matters beyond the Company\u2019s control that could impact the Company\u2019s continued compliance with Nasdaq listing requirements; the impact of management changes on the Company\u2019s business and unanticipated charges, costs and expenditures not currently contemplated that may occur as a result of management changes; and other risks and uncertainties as described in the Company\u2019s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 30, 2020, and its quarterly report on Form 10-Q filed on November 16, 2020, as well as its other filings with the SEC. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management\u2019s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210120005056\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210120005056\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Contact:<br \/>\n<br \/>Westwicke, an ICR Company<br \/>\n<br \/>Stephanie Carrington, 646-277-1282<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:stephanie.carrington@westwicke.com\">stephanie.carrington@westwicke.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America North Carolina<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210120005056\/en\/431885\/3\/TENAX_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med -Conference to be held at 4:30 pm EST on January 21, 2021- MORRISVILLE, N.C.&#8211;(BUSINESS WIRE)&#8211; Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host an investor conference call for analysts and investors on Thursday, January 21, 2021 at 4:30 p.m. EST. On the call, management will review the previously announced acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH), and the clinical development plan to advance a delayed release oral formulation of imatinib, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-417647","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med -Conference to be held at 4:30 pm EST on January 21, 2021- MORRISVILLE, N.C.&#8211;(BUSINESS WIRE)&#8211; Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host an investor conference call for analysts and investors on Thursday, January 21, 2021 at 4:30 p.m. EST. On the call, management will review the previously announced acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH), and the clinical development plan to advance a delayed release oral formulation of imatinib, &hellip; Continue reading &quot;Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-20T12:48:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med\",\"datePublished\":\"2021-01-20T12:48:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/\"},\"wordCount\":761,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/\",\"name\":\"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-20T12:48:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/","og_locale":"en_US","og_type":"article","og_title":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Market Newsdesk","og_description":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med -Conference to be held at 4:30 pm EST on January 21, 2021- MORRISVILLE, N.C.&#8211;(BUSINESS WIRE)&#8211; Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host an investor conference call for analysts and investors on Thursday, January 21, 2021 at 4:30 p.m. EST. On the call, management will review the previously announced acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH), and the clinical development plan to advance a delayed release oral formulation of imatinib, &hellip; Continue reading \"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-20T12:48:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med","datePublished":"2021-01-20T12:48:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/"},"wordCount":761,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/","name":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-20T12:48:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210120005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-schedules-conference-call-to-discuss-its-transformative-acquisition-of-ph-precision-med\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=417647"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417647\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=417647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=417647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=417647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}